Oncogene - Nature
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.

Browse Articles | Oncogene - Nature
Browse the archive of articles on Oncogene Matrix stiffness-driven cytoskeletal remodeling and tumor progression in anaplastic thyroid cancer via integrin-focal adhesion kinase signaling Chenyao ...

Research articles | Oncogene - Nature
Read the latest Research articles from Oncogene USP10 promotes cell proliferation and gemcitabine resistance in pancreatic cancer by the regulation of IGF2BP3-STEAP3 Yong-Ling Liang Cheng-Rui ...

Journal Information | Oncogene - Nature
Areas covered by Oncogene include, but are not limited to, the cellular and molecular biology of cancer including resistance to cancer therapies, and development of better approaches to improving ...

Volume 44 | Oncogene - Nature
Browse all the issues in Volume 44 of Oncogene

Oncogenes - Latest research and news | Nature
Oncogenes articles from across Nature Portfolio An oncogene is a gene that will transform a cell in culture. Oncogenes were initially identified in cancer-causing retroviruses.

Volumes | Oncogene - Nature
Oncogene (Oncogene) ISSN 1476-5594 (online) ISSN 0950-9232 (print) About Nature Portfolio About us Press releases Press office Contact us Discover content Journals A-Z Articles by subject protocols.io

Guide to Authors | Oncogene - Nature
Guide to Authors Article: An Article is a substantial, in-depth, novel research study of interest to the readership of the journal. The structure an Article should follow is detailed below ...

Comprehensive single-cell analysis reveals mast cells’ roles in cancer ...
Wenbo Wang, Jiaomeng Pan, Ming Zhao, Li Gao, Jia Zeng, Hang Gong, Guangyan Zhangyuan, Zi Li, Mao Zhang, Xia Shen, Yuanchi Weng, Xiaxing Deng & Yingying Huang Oncogene 44, 4427–4439 (2025) Cite ...

Fragment-based discovery enables direct targeting of the ... - Nature
Approximately 50% of primary melanomas harbor a hyperactivated form of the BRAF oncogene, used as a predictive biomarker of response to combinations of BRAF and MEK kinase inhibitors.